Aleafia Health Completes Breakthrough Medical Cannabis Export to Germany
Aleafia Health has successfully exported dried cannabis flower to Germany, marking a significant milestone in accessing Europe's mature cannabis market. The company is fulfilling purchase orders to Germany and has secured permits for additional shipments to Australia. CEO Geoffrey Benic highlighted that this new sales channel could provide consistent revenue. The shipment features Aleafia's THC cultivar, Sour Kush, which exceeded quality standards and did not require irradiation, giving it a competitive edge. The European cannabis market is projected to reach $4.7 billion by 2025, with Germany accounting for nearly half.
- Successful export of dried cannabis flower to Germany, enhancing market presence.
- Access to the lucrative German cannabis market expected to provide consistent revenue.
- High-quality product that did not require irradiation, presenting a competitive advantage.
- None.
TORONTO, June 03, 2021 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”), a global leader in cannabis wellness products and services, is pleased to announce that dried flower grown at its Niagara greenhouse facility has been successfully exported to Germany. Gaining access to Europe’s most mature legal cannabis market is an important breakthrough for Aleafia Health, with fulfilment of successive purchase orders to Germany currently underway.
Germany represents the second major medical cannabis market to which the Company has successfully completed exports. Import and export permits have been secured for two additional orders to Australia, with the shipments expected to occur in June.
“The investments we’ve made in the highest levels of global regulatory compliance are just now beginning to pay dividends as we gain access to the largest medical cannabis market in the world. The shipment itself is an incredibly important breakthrough. More importantly, it represents an entirely new sales channel that will deliver consistent, repeatable revenue,” said Aleafia Health CEO Geoffrey Benic. “With such high barriers to entry, the German cannabis market opportunity perfectly complements this quarter’s continued growth in our domestic medical and adult-use channels.”
The European cannabis market is expected to be worth
The first shipment features Aleafia Health’s signature THC cultivar Sour Kush. While dried flower currently available in Germany is largely irradiated, the product shipped exceeded stringent quality standards and did not require irradiation, offering a significant competitive advantage in product quality. The export was completed through the EU-GMP certified facility of a strategic partner.
For Investor & Media Relations:
Nicholas Bergamini, VP Investor Relations
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and with sales and operations in Australia and Germany. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.
Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
FAQ
What recent achievement has Aleafia Health accomplished regarding exports?
What does the export to Germany signify for Aleafia Health?
How does the German cannabis market compare to other markets?
What is Aleafia Health's signature product exported to Germany?
What competitive advantage does Aleafia's product have in Germany?
